{
    "clinical_study": {
        "@rank": "117558", 
        "arm_group": [
            {
                "arm_group_label": "Vemurafenib treatment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Digoxin treatment", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, multi-center, three-period, one sequence study will investigate the effect\n      of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable\n      BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a\n      V600-activating mutation of BRAF without acceptable standard treatment options. Patients\n      will receive multiple doses of vemurafenib in Periods B and C and a single dose of digoxin\n      in Periods A and C. Eligible patients will have the option to continue treatment with\n      vemurafenib as part of an extension study (NCT01739764). The anticipated time on study\n      treatment is approximately 36 days."
        }, 
        "brief_title": "A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma, Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients >= 18 years old\n\n          -  Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive\n             for the BRAFV600 mutation or other malignant tumor type that harbors a\n             V600-activating mutation of BRAF, as determined by results of cobas\u00ae 4800 BRAF V600\n             mutation test or a DNA sequencing method, and who have no acceptable standard\n             treatment options\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\n          -  Life expectancy >= 12 weeks\n\n          -  Full recovery from the effects of any major surgery or significant traumatic injury\n             within 14 days prior to the first dose of study treatment\n\n          -  Adequate hematologic and end organ function\n\n          -  Female patients of childbearing potential and male patients with partners of\n             childbearing potential must agree to always use two effective methods of\n             contraception\n\n          -  Negative serum pregnancy test within 7 days prior to commencement of dosing in women\n             of childbearing potential\n\n        Exclusion Criteria:\n\n          -  Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose\n             of study drug\n\n          -  Prior anti-cancer therapy within 28 days before the first dose of study drug\n\n          -  History of clinically significant cardiac or pulmonary dysfunction\n\n          -  History of symptomatic congestive heart failure of any New York Heart Association\n             class or serious cardiac arrhythmia requiring treatment\n\n          -  History of myocardial infarction within 6 months prior to first dose of study drug\n\n          -  Current dyspnea at rest, owing to complications of advanced malignancy or any\n             requirement for supplemental oxygen to perform activities of daily living\n\n          -  History of congenital long QT syndrome or QTc > 450 ms\n\n          -  Current digoxin therapy or anticipated requirement to take digoxin therapy during the\n             study\n\n          -  Active central nervous system lesions\n\n          -  Uncontrolled or poorly controlled diabetes\n\n          -  Current severe, uncontrolled systemic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765569", 
            "org_study_id": "GO28394", 
            "secondary_id": "2012-003459-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vemurafenib treatment", 
                "description": "Multiple doses of vemurafenib in Periods B and C", 
                "intervention_name": "vemurafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Digoxin treatment", 
                "description": "Single dose of digoxin in Periods A and C", 
                "intervention_name": "digoxin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Digoxin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Minsk", 
                        "country": "Belarus", 
                        "zip": "BU-220013"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minsk District", 
                        "country": "Belarus", 
                        "zip": "223040"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitebsk", 
                        "country": "Belarus", 
                        "zip": "BU-210603"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel", 
                        "zip": "6423906"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Hashomer", 
                        "country": "Israel", 
                        "zip": "52661"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "702-911"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110744"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kazan", 
                        "country": "Russian Federation", 
                        "zip": "420029"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115478"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197758"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2193"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belarus", 
                "Israel", 
                "Korea, Republic of", 
                "Russian Federation", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration time curve", 
                "safety_issue": "No", 
                "time_frame": "Approximately 36 days"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Approximately 36 days"
            }, 
            {
                "measure": "Pharmacokinetics: Time to maximum plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Approximately 36 days"
            }, 
            {
                "measure": "Pharmacokinetics: Terminal half-life", 
                "safety_issue": "No", 
                "time_frame": "Approximately 36 days"
            }, 
            {
                "measure": "Pharmacokinetics: Apparent clearance", 
                "safety_issue": "No", 
                "time_frame": "Approximately 36 days"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 36 days"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}